Galectin Therapeutics INC 10-Q quarterly reports

Galectin Therapeutics reported continued operating losses and substantial doubt regarding its ability to continue as a going concern, despite some positive signals from its NAVIGATE trial subgroup analysis.

Galectin Therapeutics reports a narrowed net loss for Q1 2026, driven by decreased R&D spending, while continuing to rely on Chairman's credit lines for liquidity.

Galectin Therapeutics reports mixed NAVIGATE trial results, a significant net loss, and ongoing liquidity concerns, despite securing new related-party financing.

Galectin Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D expenses, but faces ongoing liquidity challenges and relies on related-party financing.

Galectin Therapeutics reports its Q1 2025 financial results and continues to analyze data from the NAVIGATE clinical trial for belapectin.

Galectin Therapeutics' Q3 2024 report highlights ongoing clinical trials, a recent $6 million line of credit, and a cash runway extending to approximately May 2025.

Galectin Therapeutics reported its financial results for the second quarter of 2024 and provided an update on its clinical programs, including the anticipated interim analysis of its NAVIGATE trial.

Galectin Therapeutics reported its first quarter 2024 financial results and provided an update on its clinical development programs, including the ongoing NAVIGATE trial.